<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Antioxidants (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Antioxidants (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">antioxidants</journal-id>
<journal-title-group>
<journal-title>Antioxidants</journal-title>
</journal-title-group>
<issn pub-type="epub">2076-3921</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31035402</article-id>
<article-id pub-id-type="pmc">6562654</article-id>
<article-id pub-id-type="doi">10.3390/antiox8050111</article-id>
<article-id pub-id-type="publisher-id">antioxidants-08-00111</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Medical and Dietary Uses of N-Acetylcysteine</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8646-5754</contrib-id>
<name>
<surname>Šalamon</surname>
<given-names>Špela</given-names>
</name>
<xref ref-type="aff" rid="af1-antioxidants-08-00111">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kramar</surname>
<given-names>Barbara</given-names>
</name>
<xref ref-type="aff" rid="af2-antioxidants-08-00111">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marolt</surname>
<given-names>Tinkara Pirc</given-names>
</name>
<xref ref-type="aff" rid="af2-antioxidants-08-00111">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Poljšak</surname>
<given-names>Borut</given-names>
</name>
<xref ref-type="aff" rid="af3-antioxidants-08-00111">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6948-7238</contrib-id>
<name>
<surname>Milisav</surname>
<given-names>Irina</given-names>
</name>
<xref ref-type="aff" rid="af2-antioxidants-08-00111">2</xref>
<xref ref-type="aff" rid="af3-antioxidants-08-00111">3</xref>
<xref ref-type="corresp" rid="c1-antioxidants-08-00111">*</xref>
</contrib>
</contrib-group>
<aff id="af1-antioxidants-08-00111"><label>1</label>Center for human molecular genetics and pharmacogenomics, Faculty of Medicine, University of Maribor, SI-2000 Maribor, Slovenia; <email>spela.salamon@gmail.com</email></aff>
<aff id="af2-antioxidants-08-00111"><label>2</label>Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Zaloška 4, SI-1000 Ljubljana, Slovenia; <email>barbara.kramar@mf.uni-lj.si</email> (B.K.); <email>tinkara.pircmarolt@mf.uni-lj.si</email> (T.P.M.)</aff>
<aff id="af3-antioxidants-08-00111"><label>3</label>University of Ljubljana, Faculty of Health Sciences, Laboratory of Oxidative Stress Research, Zdravstvena pot 5, SI-1000 Ljubljana, Slovenia; <email>borut.poljsak@zf.uni-lj.si</email></aff>
<author-notes>
<corresp id="c1-antioxidants-08-00111"><label>*</label>Correspondence: <email>irina.milisav@mf.uni-lj.si</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>5</month>
<year>2019</year>
</pub-date>
<volume>8</volume>
<issue>5</issue>
<elocation-id>111</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>N-acetylcysteine (NAC), a plant antioxidant naturally found in onion, is a precursor to glutathione. It has been used as a drug since the 1960s and is listed on the World Health Organization (WHO) Model List of Essential Medicines as an antidote in poisonings. There are numerous other uses or proposed uses in medicine that are still in preclinical and clinical investigations. NAC is also used in food supplements and cosmetics. Despite its abundant use, there are projections that the NAC global market will grow in the next five years; therefore, the purpose of this work is to provide a balanced view of further uses of NAC as a dietary supplement. Although NAC is considered a safe substance, the results among clinical trials are sometimes controversial or incomplete, like for many other antioxidants. More clinical trials are underway that will improve our understanding of NAC applicability.</p>
</abstract>
<kwd-group>
<kwd>N-acetylcysteine</kwd>
<kwd>acetylcysteine</kwd>
<kwd>pharmacology</kwd>
<kwd>physiology</kwd>
<kwd>dietary supplements</kwd>
<kwd>aging</kwd>
<kwd>sports</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-antioxidants-08-00111" sec-type="intro">
<title>1. Introduction</title>
<p>N-acetylcysteine (also known as N-acetyl-cysteine, NAC) is a precursor to the amino acid L-cysteine and consequently the antioxidant glutathione (GSH) [<xref ref-type="bibr" rid="B1-antioxidants-08-00111">1</xref>]. It is most notably found in plants of the <italic>Allium</italic> species, especially in the onion (<italic>Allium cepa</italic>, 45 mg NAC/kg) [<xref ref-type="bibr" rid="B2-antioxidants-08-00111">2</xref>,<xref ref-type="bibr" rid="B3-antioxidants-08-00111">3</xref>]. The sulfhydryl group (–SH) within the NAC molecule directly scavenges reactive oxygen species (ROS) [<xref ref-type="bibr" rid="B4-antioxidants-08-00111">4</xref>], modulates the redox state of the N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (neurotransmitter effect) [<xref ref-type="bibr" rid="B5-antioxidants-08-00111">5</xref>], and inhibits the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) to modulate cytokine synthesis (anti/pro-inflammatory effect) [<xref ref-type="bibr" rid="B6-antioxidants-08-00111">6</xref>]. Unlike GSH itself, NAC has better oral and topical bioavailability [<xref ref-type="bibr" rid="B7-antioxidants-08-00111">7</xref>,<xref ref-type="bibr" rid="B8-antioxidants-08-00111">8</xref>]. Even though it has been used for more than 50 years, there are still many controversies surrounding it as a medicine as well as a dietary supplement. Several review articles have focused on various medical uses of NAC, some more general [<xref ref-type="bibr" rid="B9-antioxidants-08-00111">9</xref>] and others highly specific dealing with NAC use only in a particular condition such as hyperglycaemia-induced oxidative damage [<xref ref-type="bibr" rid="B10-antioxidants-08-00111">10</xref>], liver diseases [<xref ref-type="bibr" rid="B11-antioxidants-08-00111">11</xref>], and traumatic brain injury [<xref ref-type="bibr" rid="B12-antioxidants-08-00111">12</xref>]. Other reviews have discussed the use of NAC as a dietary supplement in psychiatric conditions by itself [<xref ref-type="bibr" rid="B13-antioxidants-08-00111">13</xref>] or in conjunction with other supplements [<xref ref-type="bibr" rid="B14-antioxidants-08-00111">14</xref>,<xref ref-type="bibr" rid="B15-antioxidants-08-00111">15</xref>]. However, we were unable to find a review of both medical and supplementary uses of NAC.</p>
</sec>
<sec id="sec2-antioxidants-08-00111">
<title>2. Molecular Mechanisms: Both Sides of the Redox Equation</title>
<p>GSH is the most abundant intracellular free thiol, and its decrease (and the increase in its redox couple oxidized glutathione, GSSG) has a crucial role in cell oxidative capacity [<xref ref-type="bibr" rid="B16-antioxidants-08-00111">16</xref>]. It is required for stem cell function [<xref ref-type="bibr" rid="B17-antioxidants-08-00111">17</xref>], and its depletion triggers cell death pathways [<xref ref-type="bibr" rid="B18-antioxidants-08-00111">18</xref>]. Cellular oxidative stress is often seen as a GSH deficiency that is characteristic of many pathological conditions such as heart disease [<xref ref-type="bibr" rid="B19-antioxidants-08-00111">19</xref>], diabetes [<xref ref-type="bibr" rid="B20-antioxidants-08-00111">20</xref>], neurodegenerative disease [<xref ref-type="bibr" rid="B21-antioxidants-08-00111">21</xref>], AIDS [<xref ref-type="bibr" rid="B22-antioxidants-08-00111">22</xref>], as well as normal aging [<xref ref-type="bibr" rid="B23-antioxidants-08-00111">23</xref>]. Though primarily seen as an antioxidant, NAC also has pro-oxidative effects. While NAC can scavenge several ROS (including HOCl, ONOO<sup>−</sup>, RO<sub>2</sub><sup>●</sup>) [<xref ref-type="bibr" rid="B24-antioxidants-08-00111">24</xref>] and hydroxyl radicals (OH<sup>●</sup>) [<xref ref-type="bibr" rid="B25-antioxidants-08-00111">25</xref>], it has a poor ability for sequestering O<sub>2</sub><sup>●−</sup> [<xref ref-type="bibr" rid="B26-antioxidants-08-00111">26</xref>] and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in vitro [<xref ref-type="bibr" rid="B27-antioxidants-08-00111">27</xref>]. NAC can behave as an oxidant by undergoing auto-oxidation in high concentrations or in the presence of transition metals. NAC can reduce transitional metals and promote the formation of ROS via Fenton-like chemistry or the production of thiyl radical:<disp-formula>NAC(SH) + Fe<sup>3+</sup> → NAC(S<sup>●−</sup>) + Fe<sup>2+</sup> + H<sup>+</sup><label>(1)</label></disp-formula></p>
<p>For example, by reducing ferric iron to its catalytic, active Fe<sup>2+</sup> form, NAC enhances the production of hydroxyl radicals in the in vitro system with Fe(III)-citrate and H<sub>2</sub>O<sub>2</sub> [<xref ref-type="bibr" rid="B28-antioxidants-08-00111">28</xref>]. Dose-dependent oxidative damage to DNA was observed in the presence of NAC in the presence of the transition metal, copper [<xref ref-type="bibr" rid="B29-antioxidants-08-00111">29</xref>]. Besides, the products of pro-oxidant reactions mediated by NAC are involved in altering the redox-sensitive NF-κB signal transduction pathway activation; mitogen activated protein kinase p38 (p38MAPK) and c-Jun N-terminal kinase (JNK) phosphorylation [<xref ref-type="bibr" rid="B30-antioxidants-08-00111">30</xref>,<xref ref-type="bibr" rid="B31-antioxidants-08-00111">31</xref>]. The antioxidant and pro-oxidant effects of NAC have been discussed in greater detail elsewhere [<xref ref-type="bibr" rid="B32-antioxidants-08-00111">32</xref>].</p>
</sec>
<sec id="sec3-antioxidants-08-00111">
<title>3. Medical Use of NAC</title>
<p>NAC has been an established drug since the 1960s; it is on the World Health Organization’s List of 40 Essential Medicines [<xref ref-type="bibr" rid="B33-antioxidants-08-00111">33</xref>] and is available as an inexpensive generic drug. It has been classically used in paracetamol overdose [<xref ref-type="bibr" rid="B34-antioxidants-08-00111">34</xref>] and as a mucolytic [<xref ref-type="bibr" rid="B35-antioxidants-08-00111">35</xref>], as well as to combat the toxicity of various substances that can cause generation of free radicals, such as carbon monoxide and x-ray contrasts [<xref ref-type="bibr" rid="B36-antioxidants-08-00111">36</xref>]. The NAC products currently approved by Food and Drug Administration (FDA) are listed in <xref ref-type="table" rid="antioxidants-08-00111-t001">Table 1</xref>. NAC is also used in the complementary treatment of neurological and neuropsychiatric disorders [<xref ref-type="bibr" rid="B5-antioxidants-08-00111">5</xref>,<xref ref-type="bibr" rid="B35-antioxidants-08-00111">35</xref>]. One death due to an anaphylactic reaction was described following an intravenous (IV) injection of 150 mg/kg of NAC in a 40 year old asthmatic woman in 2002. At comparable IV doses, vomiting was also reported in 11% of patients [<xref ref-type="bibr" rid="B37-antioxidants-08-00111">37</xref>]. However, oral NAC seems to be associated with very few side effects and is considered to have an excellent safety profile [<xref ref-type="bibr" rid="B35-antioxidants-08-00111">35</xref>]. One case of angioedema after oral NAC administration was described in 1997 [<xref ref-type="bibr" rid="B38-antioxidants-08-00111">38</xref>]. Clinical studies have revealed benefits of NAC also in non-alcoholic steatohepatitis [<xref ref-type="bibr" rid="B39-antioxidants-08-00111">39</xref>], arterial hypertension of diabetic etiology [<xref ref-type="bibr" rid="B40-antioxidants-08-00111">40</xref>], chronic obstructive pulmonary disease (COPD) [<xref ref-type="bibr" rid="B41-antioxidants-08-00111">41</xref>,<xref ref-type="bibr" rid="B42-antioxidants-08-00111">42</xref>] and chronic bronchitis [<xref ref-type="bibr" rid="B43-antioxidants-08-00111">43</xref>], substance abuse disorders [<xref ref-type="bibr" rid="B44-antioxidants-08-00111">44</xref>], recurrent unexplained pregnancy loss [<xref ref-type="bibr" rid="B45-antioxidants-08-00111">45</xref>], male infertility [<xref ref-type="bibr" rid="B46-antioxidants-08-00111">46</xref>], polycystic ovary syndrome [<xref ref-type="bibr" rid="B47-antioxidants-08-00111">47</xref>], diabetic retinopathy, age-related macular degeneration, and cataract and dry eye syndrome [<xref ref-type="bibr" rid="B4-antioxidants-08-00111">4</xref>]. In total, 300 clinical studies (291 clinical trials) of NAC are listed in ClinicalTrials.gov [<xref ref-type="bibr" rid="B48-antioxidants-08-00111">48</xref>] in April 2019 (<xref ref-type="table" rid="antioxidants-08-00111-t002">Table 2</xref>). The most common disorders that were investigated by listed interventional trials with NAC (without the currently active studies) included renal disorders (48 trials) with an emphasis on radiocontrast nephropathy prevention, chronic kidney disease, and renoprotection during surgery; and neurological and psychiatric disorders (36 trials), leading with Parkinson’s disease, schizophrenia, bipolar, autistic, and behavioral disorders. Schizophrenia, for instance, has been linked to mitochondrial abnormalities, glutathione deficiency, and increased oxidative stress in the brain. Negative and general symptoms in schizophrenia may be reduced after 8–24 weeks of adjunctive treatment with NAC [<xref ref-type="bibr" rid="B49-antioxidants-08-00111">49</xref>] in neuropsychiatric disorders and are discussed in greater detail in a recent review [<xref ref-type="bibr" rid="B50-antioxidants-08-00111">50</xref>]. Addictive disorders (23 trials) are also a common target, with alcohol, tobacco, cocaine, cannabis, and other types of dependence. The NMDA receptors that NAC modulates may be involved in addiction [<xref ref-type="bibr" rid="B51-antioxidants-08-00111">51</xref>], and at least three reviews discuss the use of NAC in addictive disorders [<xref ref-type="bibr" rid="B44-antioxidants-08-00111">44</xref>,<xref ref-type="bibr" rid="B52-antioxidants-08-00111">52</xref>,<xref ref-type="bibr" rid="B53-antioxidants-08-00111">53</xref>] and emphasize the reduction of cravings for the substance in question. Among other commonly investigated uses of NAC were applications in gastrointestinal and pulmonary diseases. The majority of the 54 currently active interventional studies are investigating the role of NAC in addictive disorders, mental health, and neurodegenerative diseases, followed by cancer/cancer treatment side-effects, cardiovascular diseases, and surgery complications/trauma.</p>
<p>The suspended, terminated, or withdrawn studies listed in ClinicalTrals.gov are in <xref ref-type="table" rid="antioxidants-08-00111-t003">Table 3</xref>. Termination reasons, such as no improvement and opposite results, are recorded in only 3 out of the 23 trials. Insufficient funds and insufficient recruitment are the major termination/ suspension/ withdrawal reason [<xref ref-type="bibr" rid="B48-antioxidants-08-00111">48</xref>]. There are a few reports of the NAC study premature termination in the literature. High doses of NAC did not improve respiratory health in patients with COPD and chronic bronchitis; the study was prematurely terminated [<xref ref-type="bibr" rid="B54-antioxidants-08-00111">54</xref>]. The decision was based on a potential safety issue, as it was reported that NAC and vitamin E, given orally, induced lung cancer in mice. This finding was reproduced in cell lines from human and mice lung tumors [<xref ref-type="bibr" rid="B55-antioxidants-08-00111">55</xref>]. Additionally, there was no indication of improvement of COPD/chronic bronchitis in the 23 patients that received 1800 mg NAC twice daily for 8 weeks compared to the equal number of subjects receiving placebo [<xref ref-type="bibr" rid="B54-antioxidants-08-00111">54</xref>]. Results of a 24-week oral NAC supplementation of cystic fibrosis patients revealed that NAC recipients maintained their lung function without a significant effect on the biomarkers of neutrophilic inflammation [<xref ref-type="bibr" rid="B56-antioxidants-08-00111">56</xref>]. Another trial was prematurely terminated in 2018 due to the absence of between-group differences in the rates of contrast-associated acute kidney injury; there was no noticeable benefit of the oral NAC on the contrast-associated acute kidney injury prevention, no noticeable improvement on the need for dialysis, persistent kidney injury or death in subjects at high risk of renal complications because of angiography [<xref ref-type="bibr" rid="B57-antioxidants-08-00111">57</xref>]. Similar conclusions were reached from the “Acetylcysteine for contrast-induced neuropathy” trial [<xref ref-type="bibr" rid="B58-antioxidants-08-00111">58</xref>].</p>
<p>Pre-clinical studies imply that NAC could have more uses in supportive care and preventing human disease. Examples include Alzheimer’s disease [<xref ref-type="bibr" rid="B59-antioxidants-08-00111">59</xref>,<xref ref-type="bibr" rid="B60-antioxidants-08-00111">60</xref>], asthma [<xref ref-type="bibr" rid="B61-antioxidants-08-00111">61</xref>], inflammatory bowel disease [<xref ref-type="bibr" rid="B62-antioxidants-08-00111">62</xref>], influenza [<xref ref-type="bibr" rid="B63-antioxidants-08-00111">63</xref>], intrauterine growth retardation [<xref ref-type="bibr" rid="B64-antioxidants-08-00111">64</xref>], obesity and insulin resistance [<xref ref-type="bibr" rid="B65-antioxidants-08-00111">65</xref>,<xref ref-type="bibr" rid="B66-antioxidants-08-00111">66</xref>,<xref ref-type="bibr" rid="B67-antioxidants-08-00111">67</xref>,<xref ref-type="bibr" rid="B68-antioxidants-08-00111">68</xref>], ischemic cardiovascular disease [<xref ref-type="bibr" rid="B69-antioxidants-08-00111">69</xref>,<xref ref-type="bibr" rid="B70-antioxidants-08-00111">70</xref>], heavy metal toxicity [<xref ref-type="bibr" rid="B71-antioxidants-08-00111">71</xref>,<xref ref-type="bibr" rid="B72-antioxidants-08-00111">72</xref>], diabetic neuropathy [<xref ref-type="bibr" rid="B73-antioxidants-08-00111">73</xref>], and age-related memory impairment [<xref ref-type="bibr" rid="B74-antioxidants-08-00111">74</xref>]. Due to its capacity to break down biofilms and improve antibiotic permeability, it is promising as an adjuvant antimicrobial drug [<xref ref-type="bibr" rid="B75-antioxidants-08-00111">75</xref>]. Several pre-clinical studies have also demonstrated that NAC supplementation leads to life extension and diminished effects of aging, in invertebrates [<xref ref-type="bibr" rid="B76-antioxidants-08-00111">76</xref>,<xref ref-type="bibr" rid="B77-antioxidants-08-00111">77</xref>,<xref ref-type="bibr" rid="B78-antioxidants-08-00111">78</xref>,<xref ref-type="bibr" rid="B79-antioxidants-08-00111">79</xref>] as well as mammals [<xref ref-type="bibr" rid="B80-antioxidants-08-00111">80</xref>] and in human breast epithelial stem cells [<xref ref-type="bibr" rid="B81-antioxidants-08-00111">81</xref>]. Such findings have yet to be replicated in humans. This is likely not solely due to NAC’s radical scavenging activity but also at least in part to telomerase activation and apoptosis inhibition [<xref ref-type="bibr" rid="B82-antioxidants-08-00111">82</xref>], as is evidenced also by its capacity to delay oocyte aging [<xref ref-type="bibr" rid="B83-antioxidants-08-00111">83</xref>]. However, antioxidants have the potential to either lengthen or shorten lifespan, depending on the dose and redox balance [<xref ref-type="bibr" rid="B84-antioxidants-08-00111">84</xref>].</p>
<p>The role of NAC in the prevention and treatment of cancer is controversial, and it is discussed in more detail below. NAC has also attracted considerable attention as a sports supplement that can reduce muscle fatigue, improve athletic performance, and aid muscle recovery [<xref ref-type="bibr" rid="B85-antioxidants-08-00111">85</xref>]. Although NAC is a well-known antioxidant and an old generic drug with several established clinical applications, more potential uses are still inadequately investigated. One of the main challenges of NAC as a medicine and a supplement is its broad range of effects and applications, far too few of which are well studied, in spite of a large effort in conducting preclinical and clinical trials.</p>
</sec>
<sec id="sec4-antioxidants-08-00111">
<title>4. NAC in Prevention and Complementary Treatment of Cancer</title>
<p>The role of antioxidants and reactive oxygen species (ROS) in cancer is controversial [<xref ref-type="bibr" rid="B86-antioxidants-08-00111">86</xref>]. Epidemiological studies on synthetic antioxidants supplementation are inconclusive and contradictory mainly due to (1) anti vs. pro-oxidative properties of antioxidant and (2) antioxidant involvement in intracellular signaling and redox regulation, which modulate proliferation, apoptosis, and gene expression [<xref ref-type="bibr" rid="B87-antioxidants-08-00111">87</xref>]. This is of particular significance during cell malignant transformation. Antioxidants in general are able to reduce the frequency of the malignant transformation by directly sequestrating ROS or by induction of cellular repair and adaptive stress responses that are important in preventing cancer initiation. For example, in experimental models of breast cancer, N-Acetylcysteine (NAC) reduced cancer aggressiveness, proliferation, and increased apoptosis of cancer cells [<xref ref-type="bibr" rid="B88-antioxidants-08-00111">88</xref>,<xref ref-type="bibr" rid="B89-antioxidants-08-00111">89</xref>]. By decreasing oxidative stress and inflammatory mediators, NAC interferes with intracellular metabolic processes by repressing glycolysis and increasing mitochondrial functioning [<xref ref-type="bibr" rid="B90-antioxidants-08-00111">90</xref>,<xref ref-type="bibr" rid="B91-antioxidants-08-00111">91</xref>]. On the other hand, antioxidant treatment may increase survival of cancer/precancer cells administered after malignant transformation [<xref ref-type="bibr" rid="B86-antioxidants-08-00111">86</xref>]. The antioxidant supplementation in tumor-bearing mice was associated with accelerated cancer progression and increased metastasis in some preclinical studies [<xref ref-type="bibr" rid="B92-antioxidants-08-00111">92</xref>,<xref ref-type="bibr" rid="B93-antioxidants-08-00111">93</xref>]. The combination of N-acetylcysteine (NAC) and soluble vitamin E analog Trolox increased the migration and invasive properties of human malignant melanoma cells in an endogenous mouse model of malignant melanoma [<xref ref-type="bibr" rid="B92-antioxidants-08-00111">92</xref>]. Similarly, N-acetylcysteine and vitamin E accelerated lung cancer progression in mice by reducing survival and increased tumor progression by disrupting the ROS-p53 axis [<xref ref-type="bibr" rid="B55-antioxidants-08-00111">55</xref>].</p>
<p>In patients undergoing cancer therapy, antioxidant supplementation may alleviate unwanted radiation and chemotherapy-induced toxicity by quenching free radicals but also reduce the efficacy of chemo- and radiotherapy. This may increase (malignant and non-malignant) cell survival by altering cellular signal transduction pathways that regulate cell proliferation [<xref ref-type="bibr" rid="B94-antioxidants-08-00111">94</xref>]. The reduction of ROS by antioxidants can lead to the survival of pre-initiated tumor cells, even in unnatural matrix environments [<xref ref-type="bibr" rid="B95-antioxidants-08-00111">95</xref>]. Thus, NAC may have dichotomous effects with respect to tumorigenesis and NAC administration may differ depending on the stage of malignant transformation. By enhancing resistance to oxidative stress and decreased apoptosis during cancer promotion, progression, and treatment stages, NAC supplementation may not always be beneficial, since it may increase cancer cell survival in altered matrix environments by antioxidant restoration of adenosine triphosphate (ATP) generation [<xref ref-type="bibr" rid="B96-antioxidants-08-00111">96</xref>]. Further clinical studies should be performed to address whether NAC administration ameliorates toxic side effects of radiation and chemotherapy with or without affecting the treatment efficacy.</p>
</sec>
<sec id="sec5-antioxidants-08-00111">
<title>5. NAC as a Dietary Supplement</title>
<p>Like many antioxidants, NAC has been very successful in the pharmaceutical, dietary supplement, and nutraceutical markets. In 2016 alone, Europe consumed approximately 3908.2 MT, USA approximately 3005.4 MT, and India approximately 1392.3 MT. The global market for NAC is expected to grow at a compound annual growth rate of about 22% over the next five years, from 490 million USD in 2017 [<xref ref-type="bibr" rid="B97-antioxidants-08-00111">97</xref>]. Sellers of dietary supplements make a number of claims about the potential of NAC to protect against environmental toxins and pollutants, treat diverse conditions, extend lifespan, and even increase testosterone levels in men—in spite of limited scientific evidence. Little to no reliable information is available about the effects experienced by numerous users of NAC as a dietary supplement. The NAC-containing product with the most reviews on Amazon.com (100% NAC powder 1 kg, 905 reviews) has an average rating of 4.6 out of 5 stars [<xref ref-type="bibr" rid="B98-antioxidants-08-00111">98</xref>]. Similar ratings can be seen for other popular NAC products. The 95 reviews on the website WebMD [<xref ref-type="bibr" rid="B99-antioxidants-08-00111">99</xref>] convey similar impressions. None of this qualifies as scientific data, but we infer that NAC is popular as a dietary supplement.</p>
</sec>
<sec id="sec6-antioxidants-08-00111">
<title>6. NAC as a Sports Supplement, Effects in Skeletal Muscle</title>
<p>The performance of NAC as a sports supplement is discussed in detail in a recent meta-analysis by Rhodes and Brakhuis [<xref ref-type="bibr" rid="B85-antioxidants-08-00111">85</xref>]. There is a great variability of study results also because of heterogenous methodologies. However, some studies have shown very significant athletic performance increases during repeated bouts of intermittent exercise (up to 50%) with NAC supplementation, particularly in athletes who have the capacity to generate more ROS in their muscles during exercise [<xref ref-type="bibr" rid="B100-antioxidants-08-00111">100</xref>]. It also appears that the benefits of NAC are more significant when muscles are in a pre-fatigued state, and thus the produced ROS can exceed the buffering capacity of the endogenous antioxidant system. One of the major challenges of using NAC as a sports supplement is in the dosage and timing of administration, which are not standardized. For example, the daily dose of NAC in the studies included by Rhodes and Brakhuis varied from 1.2 to 20 g, and the supplementation period from 8 days to minutes before the performance. The heterogenous effects of NAC in various studies reflect the fact that there is a multifactorial optimum to the redox state of various tissues that is challenging to tackle, and either too much or too little of an antioxidant can lead to performance decrease and damage. According to the Rhodes and Brakhuis meta-analysis, larger doses of NAC (&gt;5g) have an increased potential to cause side effects. Even though these side effects are generally mild and limited to gastrointestinal disturbances, they can hamper athletic performance and thus defy the purpose of supplementation. However, the evidence for these side effects is limited, and in several of the studies included in Rhodes and Brakhuis meta-analysis no side effects were reported in spite of the large doses.</p>
</sec>
<sec id="sec7-antioxidants-08-00111">
<title>7. NAC as an Anti-Aging Supplement, Effects on Degenerative Processes</title>
<p>NAC can potentially be effective in degenerative processes caused by aging, for instance, in neurodegenerative disorders, neuropathic pain, and stroke [<xref ref-type="bibr" rid="B101-antioxidants-08-00111">101</xref>]. The present findings from animal studies support a neuroprotective role of NAC in controlling age-related neurological disorders [<xref ref-type="bibr" rid="B102-antioxidants-08-00111">102</xref>]. For instance, NAC protects against Cd-induced neuronal apoptosis in mouse brain partially by inhibiting ROS-dependent activation of Akt/mTOR pathway. The findings highlight that NAC may be exploited for prevention and treatment of Cd-induced neurodegenerative diseases [<xref ref-type="bibr" rid="B103-antioxidants-08-00111">103</xref>]. Animal model results support the possibility that NAC could be explored in clinical trials for amyotrophic lateral sclerosis disease [<xref ref-type="bibr" rid="B104-antioxidants-08-00111">104</xref>], as well as Alzheimer’s disease [<xref ref-type="bibr" rid="B105-antioxidants-08-00111">105</xref>] and mild cognitive impairment [<xref ref-type="bibr" rid="B106-antioxidants-08-00111">106</xref>]. Further animal studies have shown that it delays age-associated memory impairment [<xref ref-type="bibr" rid="B74-antioxidants-08-00111">74</xref>] and improves aging-related myocardial dysfunctions [<xref ref-type="bibr" rid="B70-antioxidants-08-00111">70</xref>]. Since oxidative stress plays a prominent role in the modulation of neuropathic pain, NAC could be a potential candidate for its alleviation [<xref ref-type="bibr" rid="B107-antioxidants-08-00111">107</xref>]. Furthermore, NAC could be used in endotoxemic states to prevent oxidative damage [<xref ref-type="bibr" rid="B108-antioxidants-08-00111">108</xref>]. This warrants some caution, because NAC was associated with cardiac performance depression in a human trial [<xref ref-type="bibr" rid="B109-antioxidants-08-00111">109</xref>]. NAC has a potential to improve immune function among the elderly [<xref ref-type="bibr" rid="B110-antioxidants-08-00111">110</xref>]. A recent meta-analysis has also revealed a positive effect of NAC on human cognition, in healthy as well as mentally ill individuals [<xref ref-type="bibr" rid="B111-antioxidants-08-00111">111</xref>]. NAC may be helpful in chronic fatigue syndrome [<xref ref-type="bibr" rid="B112-antioxidants-08-00111">112</xref>]. Topical NAC may prevent UV-associated photoaging of the skin [<xref ref-type="bibr" rid="B7-antioxidants-08-00111">7</xref>]. The synthesis of GSH is decreased in the elderly, which increases oxidative stress, itself a propagator of aging. This effect can be reversed with dietary supplementation [<xref ref-type="bibr" rid="B23-antioxidants-08-00111">23</xref>]. Many medical conditions with beneficial role of NAC that are listed above are aging-associated. Based on these facts and the known molecular mechanisms of NAC as an antioxidant, we can hypothesize that it has potential as an anti-aging supplement. The dosage and timing of administration are even more of a concern here than in the case of sports supplementation, since ameliorating the effects of aging would require its long-term use. This would also raise the question of potential long-term side effects, which remains to be answered.</p>
</sec>
<sec id="sec8-antioxidants-08-00111">
<title>8. Summary and Conclusion, Future Perspectives</title>
<p>NAC is an established generic mucolytic and paracetamol poisoning antidote, but the list of conditions it can potentially improve has grown steadily over the years, and so has its popularity as a dietary supplement. In in vitro as well as in animal experiments it has exhibited potent antioxidant properties, which make NAC a powerful tool for diseases and states where ROS are the major cause of damage. However, modulating the redox state of cells, tissues, and organs is a delicate matter, and turning the dial too far in the antioxidant direction can cause more harm than good. Combined with heterogenous methodologies and a lack of standardization, the results of different studies are bound to conflict, which complicates the deduction of NAC’s effects. This is the major setback, since without determining the necessity, dosage, and timing of administration, optimal balancing of the redox scales is not possible. Developing and implementing technologies to measure the personalized levels of ROS and other oxidants and adjust the doses of antioxidants accordingly instead of using them blindly would provide an advantage, but also clinical and technological challenges. There is a wealth of unexploited information in the form of thousands of anonymous users of NAC as a dietary supplement. Since there is no regulation or documentation of this usage, we are missing out on potential information about the effects of NAC (and other antioxidants) in large numbers of people. Even though (especially oral) administration of NAC has been safe, the results of clinical trials for many conditions are still indecisive. Like other supplemented antioxidants, it may be harmful in the case of cancer or premalignancy, but there seem no other obstacles to studying NAC in many other conditions. More clinical trials of its use in neurodegenerative diseases, addiction, and mental health disorders are underway. This will provide much-needed information on NAC, and may be relevant to the supplement users. At the same time, it may help people suffering from chronic degenerative conditions.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>S.S. and B.P. wrote a manuscript draft, I.M. conceived and finalized the manuscript with inputs from all authors. B.K., T.P.M., and I.M. analyzed Clinical Trials data and produced all tables.</p>
</notes>
<notes>
<title>Funding</title>
<p>B.P. and I.M. are partially supported by Slovenian Research Agency (research core funding No. P3-0388 and P3-0019, respectively). B.K. is supported by the H2020-MSCA-ITN:721236 TREATMENT project and T.P.M. by the Slovenian Research Agency Early Stage Researcher Scheme.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-antioxidants-08-00111">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pieralisi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Soto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vila</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>L.N.</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine inhibits lipid accumulation in mouse embryonic adipocytes</article-title>
<source/>Redox Biol.
          <year>2016</year>
<volume>9</volume>
<fpage>39</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.redox.2016.05.006</pub-id>
<pub-id pub-id-type="pmid">27281491</pub-id>
</element-citation>
</ref>
<ref id="B2-antioxidants-08-00111">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diniz</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Rocha</surname>
<given-names>K.K.H.R.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Galhardi</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Ebaid</surname>
<given-names>G.M.X.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Novelli Filho</surname>
<given-names>J.L.V.B.</given-names>
</name>
<name>
<surname>Cicogna</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Novelli</surname>
<given-names>E.L.B.</given-names>
</name>
</person-group>
<article-title>Effects of N-acetylcysteine on sucrose-rich diet-induced hyperglycaemia, dyslipidemia and oxidative stress in rats</article-title>
<source/>Eur. J. Pharmacol.
          <year>2006</year>
<volume>543</volume>
<fpage>151</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2006.05.039</pub-id>
<pub-id pub-id-type="pmid">16814277</pub-id>
</element-citation>
</ref>
<ref id="B3-antioxidants-08-00111">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campos</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Diniz</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Cataneo</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Faine</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>M.J.Q.F.</given-names>
</name>
<name>
<surname>Novelli</surname>
<given-names>E.L.B.</given-names>
</name>
</person-group>
<article-title>Hypoglycaemic and antioxidant effects of onion, <italic>Allium cepa</italic>: Dietary onion addition, antioxidant activity and hypoglycaemic effects on diabetic rats</article-title>
<source/>Int. J. Food Sci. Nutr.
          <year>2003</year>
<volume>54</volume>
<fpage>241</fpage>
<lpage>246</lpage>
<pub-id pub-id-type="doi">10.1080/09637480120092062</pub-id>
<pub-id pub-id-type="pmid">12775373</pub-id>
</element-citation>
</ref>
<ref id="B4-antioxidants-08-00111">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radomska-Leśniewska</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Skopiński</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine as an anti-oxidant and anti-inflammatory drug and its some clinical applications</article-title>
<source/>Cent. J. Immunol.
          <year>2012</year>
<volume>37</volume>
<fpage>57</fpage>
<lpage>66</lpage>
</element-citation>
</ref>
<ref id="B5-antioxidants-08-00111">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bavarsad Shahripour</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Harrigan</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Alexandrov</surname>
<given-names>A.V.</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities</article-title>
<source/>Brain Behav.
          <year>2014</year>
<volume>4</volume>
<fpage>108</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1002/brb3.208</pub-id>
<pub-id pub-id-type="pmid">24683506</pub-id>
</element-citation>
</ref>
<ref id="B6-antioxidants-08-00111">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Stanniocalcin1 (STC1) Inhibits Cell Proliferation and Invasion of Cervical Cancer Cells</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<elocation-id>e53989</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0053989</pub-id>
<pub-id pub-id-type="pmid">23382863</pub-id>
</element-citation>
</ref>
<ref id="B7-antioxidants-08-00111">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Duell</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Voorhees</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Topical N-Acetyl Cysteine and Genistein Prevent Ultraviolet-Light-Induced Signaling That Leads to Photoaging in Human Skin in vivo</article-title>
<source/>J. Invest. Dermatol.
          <year>2003</year>
<volume>120</volume>
<fpage>835</fpage>
<lpage>841</lpage>
<pub-id pub-id-type="doi">10.1046/j.1523-1747.2003.12122.x</pub-id>
<pub-id pub-id-type="pmid">12713590</pub-id>
</element-citation>
</ref>
<ref id="B8-antioxidants-08-00111">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Vicenzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garrel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Denis</surname>
<given-names>F.M.</given-names>
</name>
</person-group>
<article-title>Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study</article-title>
<source/>Redox Biol.
          <year>2015</year>
<volume>6</volume>
<fpage>198</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1016/j.redox.2015.07.012</pub-id>
<pub-id pub-id-type="pmid">26262996</pub-id>
</element-citation>
</ref>
<ref id="B9-antioxidants-08-00111">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mokhtari</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Afsharian</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shahhoseini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kalantar</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Moini</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A Review on Various Uses of N-Acetyl Cysteine</article-title>
<source/>Cell J.
          <year>2017</year>
<volume>19</volume>
<fpage>11</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">28367412</pub-id>
</element-citation>
</ref>
<ref id="B10-antioxidants-08-00111">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dludla</surname>
<given-names>P.V.</given-names>
</name>
<name>
<surname>Nkambule</surname>
<given-names>B.B.</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Cardioprotective potential of N-acetyl cysteine against hyperglycaemia-induced oxidative damage: a protocol for a systematic review</article-title>
<source/>Syst. Rev.
          <year>2017</year>
<volume>6</volume>
<fpage>96</fpage>
<pub-id pub-id-type="doi">10.1186/s13643-017-0493-8</pub-id>
<pub-id pub-id-type="pmid">28499416</pub-id>
</element-citation>
</ref>
<ref id="B11-antioxidants-08-00111">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Andrade</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Moura</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>dos Santos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>de Araújo</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>de Farias Santos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goulart</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Andrade</surname>
<given-names>K.Q.</given-names>
</name>
<name>
<surname>Moura</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Dos Santos</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>De Araújo</surname>
<given-names>O.R.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine</article-title>
<source/>Int. J. Mol. Sci.
          <year>2015</year>
<volume>16</volume>
<fpage>30269</fpage>
<lpage>30308</lpage>
<pub-id pub-id-type="doi">10.3390/ijms161226225</pub-id>
<pub-id pub-id-type="pmid">26694382</pub-id>
</element-citation>
</ref>
<ref id="B12-antioxidants-08-00111">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffer</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Pick</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Hoffer</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Chiang</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Greig</surname>
<given-names>N.H.</given-names>
</name>
</person-group>
<article-title>Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine</article-title>
<source/>J. Biomed. Sci.
          <year>2017</year>
<volume>24</volume>
<fpage>71</fpage>
<pub-id pub-id-type="doi">10.1186/s12929-017-0377-1</pub-id>
<pub-id pub-id-type="pmid">28886718</pub-id>
</element-citation>
</ref>
<ref id="B13-antioxidants-08-00111">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Giaroli</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>What Future Role Might N-Acetyl-Cysteine Have in the Treatment of Obsessive Compulsive and Grooming Disorders?</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2016</year>
<volume>36</volume>
<fpage>57</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0000000000000431</pub-id>
<pub-id pub-id-type="pmid">26629962</pub-id>
</element-citation>
</ref>
<ref id="B14-antioxidants-08-00111">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plemenitaš</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Prehrana in prehranska dopolnila v psihiatriji</article-title>
<source/>Slov. Med. J.
          <year>2018</year>
<volume>87</volume>
<fpage>1</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="doi">10.6016/ZdravVestn.2484</pub-id>
</element-citation>
</ref>
<ref id="B15-antioxidants-08-00111">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>di Michele</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Siracusano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Talamo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Niolu</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>N-Acetyl Cysteine and Vitamin D Supplementation in Treatment Resistant Obsessive-compulsive Disorder Patients: A General Review</article-title>
<source/>Curr. Pharm. Des.
          <year>2018</year>
<volume>24</volume>
<fpage>1832</fpage>
<lpage>1838</lpage>
<pub-id pub-id-type="doi">10.2174/1381612824666180417124919</pub-id>
<pub-id pub-id-type="pmid">29663874</pub-id>
</element-citation>
</ref>
<ref id="B16-antioxidants-08-00111">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schafer</surname>
<given-names>F.Q.</given-names>
</name>
<name>
<surname>Buettner</surname>
<given-names>G.R.</given-names>
</name>
</person-group>
<article-title>Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple</article-title>
<source/>Free Radic. Biol. Med.
          <year>2001</year>
<volume>30</volume>
<fpage>1191</fpage>
<lpage>1212</lpage>
<pub-id pub-id-type="doi">10.1016/S0891-5849(01)00480-4</pub-id>
<pub-id pub-id-type="pmid">11368918</pub-id>
</element-citation>
</ref>
<ref id="B17-antioxidants-08-00111">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Heo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.-J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Real-Time Monitoring of Glutathione in Living Cells Reveals that High Glutathione Levels Are Required to Maintain Stem Cell Function</article-title>
<source/>Stem Cell Rep.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2017.12.007</pub-id>
</element-citation>
</ref>
<ref id="B18-antioxidants-08-00111">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cidlowski</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Glutathione efflux and cell death</article-title>
<source/>Antioxid. Redox Signal.
          <year>2012</year>
<volume>17</volume>
<fpage>1694</fpage>
<lpage>1713</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2012.4553</pub-id>
<pub-id pub-id-type="pmid">22656858</pub-id>
</element-citation>
</ref>
<ref id="B19-antioxidants-08-00111">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damy</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kirsch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khouzami</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Caramelle</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Le Corvoisier</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Roudot-Thoraval</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dubois-Randé</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Hittinger</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pavoine</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pecker</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Glutathione Deficiency in Cardiac Patients is Related to the Functional Status and Structural Cardiac Abnormalities</article-title>
<source/>PLoS One
          <year>2009</year>
<volume>4</volume>
<elocation-id>e4871</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0004871</pub-id>
<pub-id pub-id-type="pmid">19319187</pub-id>
</element-citation>
</ref>
<ref id="B20-antioxidants-08-00111">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lutchmansingh</surname>
<given-names>F.K.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>F.I.</given-names>
</name>
<name>
<surname>Badaloo</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>McFarlane-Anderson</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gordon-Strachan</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Wright-Pascoe</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Jahoor</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Boyne</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Glutathione metabolism in type 2 diabetes and its relationship with microvascular complications and glycemia</article-title>
<source/>PLoS One
          <year>2018</year>
<volume>13</volume>
<elocation-id>e0198626</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0198626</pub-id>
<pub-id pub-id-type="pmid">29879181</pub-id>
</element-citation>
</ref>
<ref id="B21-antioxidants-08-00111">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doss</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rinnenthal</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Schmitz-Hübsch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>A.U.</given-names>
</name>
<name>
<surname>Papazoglou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lux</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maul</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Würfel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Endres</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Klockgether</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency</article-title>
<source/>J. Neurol.
          <year>2015</year>
<volume>262</volume>
<fpage>1927</fpage>
<lpage>1935</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-015-7788-2</pub-id>
<pub-id pub-id-type="pmid">26041613</pub-id>
</element-citation>
</ref>
<ref id="B22-antioxidants-08-00111">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dröge</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Cysteine and Glutathione Deficiency in AIDS Patients: A Rationale for the Treatment with IM-Acetyl-Cysteine</article-title>
<source/>Pharmacol.
          <year>1993</year>
<volume>46</volume>
<fpage>61</fpage>
<lpage>65</lpage>
</element-citation>
</ref>
<ref id="B23-antioxidants-08-00111">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekhar</surname>
<given-names>R.V.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Guthikonda</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Balasubramanyam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Taffet</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Jahoor</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation</article-title>
<source/>Am. J. Clin. Nutr.
          <year>2011</year>
<volume>94</volume>
<fpage>847</fpage>
<lpage>853</lpage>
<pub-id pub-id-type="doi">10.3945/ajcn.110.003483</pub-id>
<pub-id pub-id-type="pmid">21795440</pub-id>
</element-citation>
</ref>
<ref id="B24-antioxidants-08-00111">
<label>24.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Halliwell</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gutteridge</surname>
<given-names>J.M.C.</given-names>
</name>
</person-group>
<source/>Free Radicals in Biology and Medicine
          <edition>4th ed.</edition>
<publisher-name>Oxford University Press</publisher-name>
<publisher-loc>Oxford, UK</publisher-loc>
<year>2007</year>
</element-citation>
</ref>
<ref id="B25-antioxidants-08-00111">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aruoma</surname>
<given-names>O.I.</given-names>
</name>
<name>
<surname>Halliwell</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hoey</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid</article-title>
<source/>Free Radic. Biol. Med.
          <year>1989</year>
<volume>6</volume>
<fpage>593</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="doi">10.1016/0891-5849(89)90066-X</pub-id>
<pub-id pub-id-type="pmid">2546864</pub-id>
</element-citation>
</ref>
<ref id="B26-antioxidants-08-00111">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benrahmoune</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Thérond</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Abedinzadeh</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>The reaction of superoxide radical with N-acetylcysteine</article-title>
<source/>Free Radic. Biol. Med.
          <year>2000</year>
<volume>29</volume>
<fpage>775</fpage>
<lpage>782</lpage>
<pub-id pub-id-type="doi">10.1016/S0891-5849(00)00380-4</pub-id>
<pub-id pub-id-type="pmid">11053779</pub-id>
</element-citation>
</ref>
<ref id="B27-antioxidants-08-00111">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moldéus</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cotgreave</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Berggren</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Lung Protection by a Thiol-Containing Antioxidant: N-Acetylcysteine</article-title>
<source/>Respiration
          <year>1986</year>
<volume>50</volume>
<fpage>31</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1159/000195086</pub-id>
<pub-id pub-id-type="pmid">3809741</pub-id>
</element-citation>
</ref>
<ref id="B28-antioxidants-08-00111">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corinne Sprong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Winkelhuyzen-Janssen</surname>
<given-names>A.M.L.</given-names>
</name>
<name>
<surname>Aarsman</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>van Oirschot</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>van der Bruggen</surname>
<given-names>T.J.O.M.M.E.</given-names>
</name>
<name>
<surname>Sweder van Asbeck</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Low-dose <italic>N</italic>-Acetylcysteine Protects Rats against Endotoxin-mediated Oxidative Stress, But High-dose Increases Mortality</article-title>
<source/>Am. J. Respir. Crit. Care Med.
          <year>1998</year>
<volume>157</volume>
<fpage>1283</fpage>
<lpage>1293</lpage>
<pub-id pub-id-type="doi">10.1164/ajrccm.157.4.9508063</pub-id>
<pub-id pub-id-type="pmid">9563752</pub-id>
</element-citation>
</ref>
<ref id="B29-antioxidants-08-00111">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spear</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Aust</surname>
<given-names>S.D.</given-names>
</name>
</person-group>
<article-title>Hydroxylation of Deoxyguanosine in DNA by Copper and Thiols</article-title>
<source/>Arch. Biochem. Biophys.
          <year>1995</year>
<volume>317</volume>
<fpage>142</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1006/abbi.1995.1146</pub-id>
<pub-id pub-id-type="pmid">7872776</pub-id>
</element-citation>
</ref>
<ref id="B30-antioxidants-08-00111">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Lewis-Molock</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Activation of NF-kappa B and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells</article-title>
<source/>Am. J. Physiol. Cell. Mol. Physiol.
          <year>1995</year>
<volume>269</volume>
<fpage>L588</fpage>
<lpage>L602</lpage>
<pub-id pub-id-type="doi">10.1152/ajplung.1995.269.5.L588</pub-id>
<pub-id pub-id-type="pmid">7491977</pub-id>
</element-citation>
</ref>
<ref id="B31-antioxidants-08-00111">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Riches</surname>
<given-names>D.W.H.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Redox Paradox: Effect of N-Acetylcysteine and Serum on Oxidation Reduction–Sensitive Mitogen-Activated Protein Kinase Signaling Pathways</article-title>
<source/>Am. J. Respir. Cell Mol. Biol.
          <year>2001</year>
<volume>24</volume>
<fpage>627</fpage>
<lpage>632</lpage>
<pub-id pub-id-type="doi">10.1165/ajrcmb.24.5.4280</pub-id>
<pub-id pub-id-type="pmid">11350834</pub-id>
</element-citation>
</ref>
<ref id="B32-antioxidants-08-00111">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sagristá</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>García</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Africa De Madariaga</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mora</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Antioxidant and pro-oxidant effect of the thiolic compounds N-acetyl-L-cysteine and glutathione against free radical-induced lipid peroxidation</article-title>
<source/>Free Radic. Res.
          <year>2002</year>
<volume>36</volume>
<fpage>329</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="doi">10.1080/10715760290019354</pub-id>
<pub-id pub-id-type="pmid">12071352</pub-id>
</element-citation>
</ref>
<ref id="B33-antioxidants-08-00111">
<label>33.</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>
<article-title>WHO Model List of Essential Medicines: 20th List</article-title>
<month>3</month>
<year>2017</year>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amendedAug2017.pdf?ua=1">http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amendedAug2017.pdf?ua=1</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-03-27">(accessed on 27 March 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B34-antioxidants-08-00111">
<label>34.</label>
<element-citation publication-type="gov">
<person-group person-group-type="author">
<collab>FDA</collab>
</person-group>
<article-title>Acetadote (acetylcysteine) Injection Package Insert</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-539_Acetadote.cfm">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-539_Acetadote.cfm</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-03-27">(accessed on 27 March 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B35-antioxidants-08-00111">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slattery</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Delhey</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Spielholz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2015</year>
<volume>55</volume>
<fpage>294</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="pmid">25957927</pub-id>
</element-citation>
</ref>
<ref id="B36-antioxidants-08-00111">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pannu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Manns</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tonelli</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Systematic review of the impact of N-acetylcysteine on contrast nephropathy</article-title>
<source/>Kidney Int.
          <year>2004</year>
<volume>65</volume>
<fpage>1366</fpage>
<lpage>1374</lpage>
<pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00516.x</pub-id>
<pub-id pub-id-type="pmid">15086476</pub-id>
</element-citation>
</ref>
<ref id="B37-antioxidants-08-00111">
<label>37.</label>
<element-citation publication-type="gov">
<person-group person-group-type="author">
<collab>Center for Drug Evaluation and Research</collab>
</person-group>
<article-title>Application no. 21-539. Medical Review (Robert Prizont, MD), 2003</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-539_Acetadote_Medr.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-539_Acetadote_Medr.pdf</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-02-13">(accessed on 13 February 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B38-antioxidants-08-00111">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mroz</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Benitez</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Krenzelok</surname>
<given-names>E.P.</given-names>
</name>
</person-group>
<article-title>Angioedema with oral N-acetylcysteine</article-title>
<source/>Ann. Emerg. Med.
          <year>1997</year>
<volume>30</volume>
<fpage>240</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">9250658</pub-id>
</element-citation>
</ref>
<ref id="B39-antioxidants-08-00111">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Oliveira</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Stefano</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>De Siqueira</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>De Campos Mazo</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Furuya</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Mello</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>F.G.</given-names>
</name>
<name>
<surname>Rabello</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis</article-title>
<source/>Hepatol. Res.
          <year>2008</year>
<volume>38</volume>
<fpage>159</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1111/j.1872-034X.2007.00215.x</pub-id>
<pub-id pub-id-type="pmid">18197877</pub-id>
</element-citation>
</ref>
<ref id="B40-antioxidants-08-00111">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martina</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Masha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gigliardi</surname>
<given-names>V.R.</given-names>
</name>
<name>
<surname>Brocato</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Manzato</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Berchio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Massarenti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Settanni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Della Casa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bergamini</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long Term N-Acetylcysteine and L-Arginine Administration Reduces Endothelial Activation and Systolic Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus</article-title>
<source/>Diabetes Care
          <year>2008</year>
<volume>31</volume>
<fpage>940</fpage>
<lpage>944</lpage>
<pub-id pub-id-type="doi">10.2337/dc07-2251</pub-id>
<pub-id pub-id-type="pmid">18268065</pub-id>
</element-citation>
</ref>
<ref id="B41-antioxidants-08-00111">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tse</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>C.Z.S.</given-names>
</name>
</person-group>
<article-title>Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease</article-title>
<source/>Int. J. Chron. Obstruct. Pulmon. Dis.
          <year>2014</year>
<volume>9</volume>
<fpage>825</fpage>
<lpage>836</lpage>
<pub-id pub-id-type="doi">10.2147/COPD.S51057</pub-id>
<pub-id pub-id-type="pmid">25125976</pub-id>
</element-citation>
</ref>
<ref id="B42-antioxidants-08-00111">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pirabbasi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shahar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Manaf</surname>
<given-names>Z.A.</given-names>
</name>
<name>
<surname>Rajab</surname>
<given-names>N.F.</given-names>
</name>
<name>
<surname>Manap</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Efficacy of Ascorbic Acid (Vitamin C) and/N-Acetylcysteine (NAC) Supplementation on Nutritional and Antioxidant Status of Male Chronic Obstructive Pulmonary Disease (COPD) Patients</article-title>
<source/>J. Nutr. Sci. Vitaminol. (Tokyo)
          <year>2016</year>
<volume>62</volume>
<fpage>54</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.3177/jnsv.62.54</pub-id>
<pub-id pub-id-type="pmid">27117852</pub-id>
</element-citation>
</ref>
<ref id="B43-antioxidants-08-00111">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stey</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Steurer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bachmann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Medici</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Tramèr</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review</article-title>
<source/>Eur. Respir. J.
          <year>2000</year>
<volume>16</volume>
<fpage>253</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1034/j.1399-3003.2000.16b12.x</pub-id>
<pub-id pub-id-type="pmid">10968500</pub-id>
</element-citation>
</ref>
<ref id="B44-antioxidants-08-00111">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McClure</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Gipson</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Malcolm</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Kalivas</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>Potential role of N-acetylcysteine in the management of substance use disorders</article-title>
<source/>CNS Drugs
          <year>2014</year>
<volume>28</volume>
<fpage>95</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1007/s40263-014-0142-x</pub-id>
<pub-id pub-id-type="pmid">24442756</pub-id>
</element-citation>
</ref>
<ref id="B45-antioxidants-08-00111">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amin</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Shaaban</surname>
<given-names>O.M.</given-names>
</name>
<name>
<surname>Bediawy</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>N-acetyl cysteine for treatment of recurrent unexplained pregnancy loss</article-title>
<source/>Reprod. Biomed. Online
          <year>2008</year>
<volume>17</volume>
<fpage>722</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1016/S1472-6483(10)60322-7</pub-id>
<pub-id pub-id-type="pmid">18983759</pub-id>
</element-citation>
</ref>
<ref id="B46-antioxidants-08-00111">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Safarinejad</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Safarinejad</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Efficacy of Selenium and/or N-Acetyl-Cysteine for Improving Semen Parameters in Infertile Men: A Double-Blind, Placebo Controlled, Randomized Study</article-title>
<source/>J. Urol.
          <year>2009</year>
<volume>181</volume>
<fpage>741</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="doi">10.1016/j.juro.2008.10.015</pub-id>
<pub-id pub-id-type="pmid">19091331</pub-id>
</element-citation>
</ref>
<ref id="B47-antioxidants-08-00111">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fulghesu</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Ciampelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Muzj</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Belosi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Selvaggi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ayala</surname>
<given-names>G.F.</given-names>
</name>
<name>
<surname>Lanzone</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome</article-title>
<source/>Fertil. Steril.
          <year>2002</year>
<volume>77</volume>
<fpage>1128</fpage>
<lpage>1135</lpage>
<pub-id pub-id-type="doi">10.1016/S0015-0282(02)03133-3</pub-id>
<pub-id pub-id-type="pmid">12057717</pub-id>
</element-citation>
</ref>
<ref id="B48-antioxidants-08-00111">
<label>48.</label>
<element-citation publication-type="gov">
<article-title>ClinicalTrials.gov</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-04-02">(accessed on 2 April 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B49-antioxidants-08-00111">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Chibnall</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Nasrallah</surname>
<given-names>H.A.</given-names>
</name>
</person-group>
<article-title>Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review</article-title>
<source/>Ann. Clin. Psychiatry
          <year>2016</year>
<volume>28</volume>
<fpage>190</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="pmid">27490835</pub-id>
</element-citation>
</ref>
<ref id="B50-antioxidants-08-00111">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rapado-Castro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Malhi</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Skvarc</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>On</surname>
<given-names>Z.X.</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>O.M.</given-names>
</name>
</person-group>
<article-title>Cognitive effects of adjunctive N-acetyl cysteine in psychosis</article-title>
<source/>Psychol. Med.
          <year>2017</year>
<volume>47</volume>
<fpage>866</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="doi">10.1017/S0033291716002932</pub-id>
<pub-id pub-id-type="pmid">27894373</pub-id>
</element-citation>
</ref>
<ref id="B51-antioxidants-08-00111">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopf</surname>
<given-names>F.W.</given-names>
</name>
</person-group>
<article-title>Do specific NMDA receptor subunits act as gateways for addictive behaviors?</article-title>
<source/>Genes. Brain. Behav.
          <year>2017</year>
<volume>16</volume>
<fpage>118</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="doi">10.1111/gbb.12348</pub-id>
<pub-id pub-id-type="pmid">27706932</pub-id>
</element-citation>
</ref>
<ref id="B52-antioxidants-08-00111">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomko</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Gilmore</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Back</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine: A potential treatment for substance use disorders</article-title>
<source/>Curr. Psychiatr.
          <year>2018</year>
<volume>17</volume>
<fpage>30</fpage>
<lpage>55</lpage>
<page-range>30–36, 41–42, 55</page-range>
<pub-id pub-id-type="pmid">30016376</pub-id>
</element-citation>
</ref>
<ref id="B53-antioxidants-08-00111">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nocito Echevarria</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Andrade Reis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ruffo Capatti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Siciliano Soares</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>da Silveira</surname>
<given-names>D.X.</given-names>
</name>
<name>
<surname>Fidalgo</surname>
<given-names>T.M.</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine for treating cocaine addiction – A systematic review</article-title>
<source/>Psychiatry Res.
          <year>2017</year>
<volume>251</volume>
<fpage>197</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2017.02.024</pub-id>
<pub-id pub-id-type="pmid">28213190</pub-id>
</element-citation>
</ref>
<ref id="B54-antioxidants-08-00111">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McEvoy</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Naqvi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wendt</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reilkoff</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Kunisaki</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Wetherbee</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tirouvanziam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Niewoehner</surname>
<given-names>D.E.</given-names>
</name>
</person-group>
<article-title>High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: A randomized, placebo-controlled trial</article-title>
<source/>Int. J. Chron. Obstruct. Pulmon. Dis.
          <year>2016</year>
<volume>11</volume>
<fpage>799</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="pmid">27143871</pub-id>
</element-citation>
</ref>
<ref id="B55-antioxidants-08-00111">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sayin</surname>
<given-names>V.I.</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>M.X.</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Lindahl</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bergo</surname>
<given-names>M.O.</given-names>
</name>
</person-group>
<article-title>Antioxidants Accelerate Lung Cancer Progression in Mice</article-title>
<source/>Sci. Transl. Med.
          <year>2014</year>
<volume>6</volume>
<fpage>221ra15</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3007653</pub-id>
</element-citation>
</ref>
<ref id="B56-antioxidants-08-00111">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conrad</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lymp</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chatfield</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nichols</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Clancy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vender</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>M.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial</article-title>
<source/>J. Cyst. Fibros.
          <year>2015</year>
<volume>14</volume>
<fpage>219</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcf.2014.08.008</pub-id>
<pub-id pub-id-type="pmid">25228446</pub-id>
</element-citation>
</ref>
<ref id="B57-antioxidants-08-00111">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weisbord</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jneid</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cass</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thwin</surname>
<given-names>S.-S.</given-names>
</name>
<name>
<surname>Conner</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Chertow</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Bhatt</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Shunk</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine</article-title>
<source/>N. Engl. J. Med.
          <year>2018</year>
<volume>378</volume>
<fpage>603</fpage>
<lpage>614</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1710933</pub-id>
<pub-id pub-id-type="pmid">29130810</pub-id>
</element-citation>
</ref>
<ref id="B58-antioxidants-08-00111">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>ACT Investigators</collab>
</person-group>
<article-title>Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography</article-title>
<source/>Circulation
          <year>2011</year>
<volume>124</volume>
<fpage>1250</fpage>
<lpage>1259</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.038943</pub-id>
<pub-id pub-id-type="pmid">21859972</pub-id>
</element-citation>
</ref>
<ref id="B59-antioxidants-08-00111">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreira</surname>
<given-names>P.I.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>P.L.R.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts</article-title>
<source/>J. Alzheimers. Dis.
          <year>2007</year>
<volume>12</volume>
<fpage>195</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2007-12210</pub-id>
<pub-id pub-id-type="pmid">17917164</pub-id>
</element-citation>
</ref>
<ref id="B60-antioxidants-08-00111">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parachikova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>K.N.</given-names>
</name>
<name>
<surname>Hendrix</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Laferla</surname>
<given-names>F.M.</given-names>
</name>
</person-group>
<article-title>Formulation of a medical food cocktail for Alzheimer’s disease: Beneficial effects on cognition and neuropathology in a mouse model of the disease</article-title>
<source/>PLoS One
          <year>2010</year>
<volume>5</volume>
<elocation-id>e14015</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0014015</pub-id>
<pub-id pub-id-type="pmid">21103342</pub-id>
</element-citation>
</ref>
<ref id="B61-antioxidants-08-00111">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blesa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cortijo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martinez-losa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Seda</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Santangelo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Morcillo</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Effectiveness of oral N-acetylcysteine in a rat experimental model of asthma</article-title>
<source/>Pharmacol. Res.
          <year>2002</year>
<volume>45</volume>
<fpage>135</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1006/phrs.2001.0917</pub-id>
<pub-id pub-id-type="pmid">11846626</pub-id>
</element-citation>
</ref>
<ref id="B62-antioxidants-08-00111">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Protective effects of N-acetylcysteine on acetic acid-induced colitis in a porcine model</article-title>
<source/>BMC Gastroenterol.
          <year>2013</year>
<volume>13</volume>
<elocation-id>133</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-230X-13-133</pub-id>
<pub-id pub-id-type="pmid">24001404</pub-id>
</element-citation>
</ref>
<ref id="B63-antioxidants-08-00111">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anfossi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Massucco</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mattiello</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cavalot</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Trovati</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets</article-title>
<source/>Eur. J. Clin. Invest.
          <year>2001</year>
<volume>31</volume>
<fpage>452</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2362.2001.00815.x</pub-id>
<pub-id pub-id-type="pmid">11380598</pub-id>
</element-citation>
</ref>
<ref id="B64-antioxidants-08-00111">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>N-Acetylcysteine protects against intrauterine growth retardation-induced intestinal injury via restoring redox status and mitochondrial function in neonatal piglets</article-title>
<source/>Eur. J. Nutr.
          <year>2018</year>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1007/s00394-018-1878-8</pub-id>
</element-citation>
</ref>
<ref id="B65-antioxidants-08-00111">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calzadilla</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gómez-Serrano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>García-Santos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Schiappacasse</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abalde</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Peral</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>L.N.</given-names>
</name>
</person-group>
<article-title><italic>N</italic> -Acetylcysteine affects obesity-related protein expression in 3T3-L1 adipocytes</article-title>
<source/>Redox Rep.
          <year>2013</year>
<volume>18</volume>
<fpage>210</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="doi">10.1179/1351000213Y.0000000066</pub-id>
<pub-id pub-id-type="pmid">24112955</pub-id>
</element-citation>
</ref>
<ref id="B66-antioxidants-08-00111">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J.-R.</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>H.-H.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Kwun</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Association of anti-obesity activity of N-acetylcysteine with metallothionein-II down-regulation</article-title>
<source/>Exp. Mol. Med.
          <year>2006</year>
<volume>38</volume>
<fpage>162</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1038/emm.2006.20</pub-id>
<pub-id pub-id-type="pmid">16672770</pub-id>
</element-citation>
</ref>
<ref id="B67-antioxidants-08-00111">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novelli</surname>
<given-names>E.L.B.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Assalin</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rocha</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ebaid</surname>
<given-names>G.X.</given-names>
</name>
<name>
<surname>Seiva</surname>
<given-names>F.R.F.</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine in high-sucrose diet-induced obesity: Energy expenditure and metabolic shifting for cardiac health</article-title>
<source/>Pharmacol. Res.
          <year>2009</year>
<volume>59</volume>
<fpage>74</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2008.10.004</pub-id>
<pub-id pub-id-type="pmid">18996201</pub-id>
</element-citation>
</ref>
<ref id="B68-antioxidants-08-00111">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>F.-C.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>S.-W.</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>C.-F.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.-Y.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C.-S.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>W.-S.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T.-K.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>C.-W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early intervention of N-acetylcysteine better improves insulin resistance in diet-induced obesity mice</article-title>
<source/>Free Radic. Res.
          <year>2018</year>
<volume>52</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1080/10715762.2018.1447670</pub-id>
<pub-id pub-id-type="pmid">29166803</pub-id>
</element-citation>
</ref>
<ref id="B69-antioxidants-08-00111">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ooie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shinohara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Saikawa</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Oral Administration of Geranylgeranylacetone Blunts the Endothelial Dysfunction Induced by Ischemia and Reperfusion in the Rat Heart</article-title>
<source/>J. Cardiovasc. Pharmacol.
          <year>2005</year>
<volume>45</volume>
<fpage>555</fpage>
<lpage>562</lpage>
<pub-id pub-id-type="doi">10.1097/01.fjc.0000159879.04444.22</pub-id>
<pub-id pub-id-type="pmid">15897783</pub-id>
</element-citation>
</ref>
<ref id="B70-antioxidants-08-00111">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemmeryckx</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hohensinner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Swinnen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heggermont</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wojta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lijnen</surname>
<given-names>H.R.</given-names>
</name>
</person-group>
<article-title>Antioxidant Treatment Improves Cardiac Dysfunction in a Murine Model of Premature Aging</article-title>
<source/>J. Cardiovasc. Pharmacol.
          <year>2016</year>
<volume>68</volume>
<fpage>374</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1097/FJC.0000000000000423</pub-id>
<pub-id pub-id-type="pmid">27824722</pub-id>
</element-citation>
</ref>
<ref id="B71-antioxidants-08-00111">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jahejo</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protective effects of zinc and N-acetyl-L-cysteine supplementation against cadmium induced erythrocyte cytotoxicity in Arbor Acres broiler chickens (Gallus gallus domesticus)</article-title>
<source/>Ecotoxicol. Environ. Saf.
          <year>2018</year>
<volume>163</volume>
<fpage>331</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="doi">10.1016/j.ecoenv.2018.07.069</pub-id>
<pub-id pub-id-type="pmid">30059877</pub-id>
</element-citation>
</ref>
<ref id="B72-antioxidants-08-00111">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flora</surname>
<given-names>S.J.S.</given-names>
</name>
</person-group>
<article-title>Structural, chemical and biological aspects of antioxidants for strategies against metal and metalloid exposure</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2009</year>
<volume>2</volume>
<fpage>191</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.4161/oxim.2.4.9112</pub-id>
<pub-id pub-id-type="pmid">20716905</pub-id>
</element-citation>
</ref>
<ref id="B73-antioxidants-08-00111">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sagara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Satoh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yagihashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fukuzawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Muto</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Muto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Toyota</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine</article-title>
<source/>Diabetologia
          <year>1996</year>
<volume>39</volume>
<fpage>263</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1007/BF00418340</pub-id>
<pub-id pub-id-type="pmid">8721770</pub-id>
</element-citation>
</ref>
<ref id="B74-antioxidants-08-00111">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martínez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hernández</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Martínez</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>N-Acetylcysteine delays age-associated memory impairment in mice: role in synaptic mitochondria</article-title>
<source/>Brain Res.
          <year>2000</year>
<volume>855</volume>
<fpage>100</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(99)02349-5</pub-id>
<pub-id pub-id-type="pmid">10650135</pub-id>
</element-citation>
</ref>
<ref id="B75-antioxidants-08-00111">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinicola</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Grazia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carlomagno</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pintucci</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review</article-title>
<source/>Eur. Rev. Med. Pharmacol. Sci.
          <year>2014</year>
<volume>18</volume>
<fpage>2942</fpage>
<lpage>2948</lpage>
<pub-id pub-id-type="pmid">25339490</pub-id>
</element-citation>
</ref>
<ref id="B76-antioxidants-08-00111">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brack</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bechter-Thüring</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Labuhn</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>N-Acetylcysteine slows down ageing and increases the life span of Drosophila melanogaster</article-title>
<source/>Cell. Mol. Life Sci.
          <year>1997</year>
<volume>53</volume>
<fpage>960</fpage>
<lpage>966</lpage>
<pub-id pub-id-type="doi">10.1007/PL00013199</pub-id>
<pub-id pub-id-type="pmid">9447249</pub-id>
</element-citation>
</ref>
<ref id="B77-antioxidants-08-00111">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Lifespan extension and increased resistance to environmental stressors by N-Acetyl-L-Cysteine in Caenorhabditis elegans</article-title>
<source/>Clinics
          <year>2015</year>
<volume>70</volume>
<fpage>380</fpage>
<lpage>386</lpage>
<pub-id pub-id-type="doi">10.6061/clinics/2015(05)13</pub-id>
<pub-id pub-id-type="pmid">26039957</pub-id>
</element-citation>
</ref>
<ref id="B78-antioxidants-08-00111">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaposhnikov</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Zemskaya</surname>
<given-names>N.V.</given-names>
</name>
<name>
<surname>Koval</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Schegoleva</surname>
<given-names>E.V.</given-names>
</name>
<name>
<surname>Zhavoronkov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Moskalev</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>Effects of N-acetyl-L-cysteine on lifespan, locomotor activity and stress-resistance of 3 Drosophila species with different lifespans</article-title>
<source/>Aging (Albany NY)
          <year>2018</year>
<volume>10</volume>
<fpage>2428</fpage>
<lpage>2458</lpage>
<pub-id pub-id-type="doi">10.18632/aging.101561</pub-id>
<pub-id pub-id-type="pmid">30243020</pub-id>
</element-citation>
</ref>
<ref id="B79-antioxidants-08-00111">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>S.-I.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.-K.</given-names>
</name>
</person-group>
<article-title>N-acetyl-l-cysteine mimics the effect of dietary restriction on lifespan and reduces amyloid beta-induced toxicity in Caenorhabditis elegans</article-title>
<source/>Food Sci. Biotechnol.
          <year>2017</year>
<volume>26</volume>
<fpage>783</fpage>
<lpage>790</lpage>
<pub-id pub-id-type="doi">10.1007/s10068-017-0079-1</pub-id>
<pub-id pub-id-type="pmid">30263604</pub-id>
</element-citation>
</ref>
<ref id="B80-antioxidants-08-00111">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flurkey</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Astle</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>D.E.</given-names>
</name>
</person-group>
<article-title>Life Extension by Diet Restriction and N-Acetyl-L-Cysteine in Genetically Heterogeneous Mice</article-title>
<source/>J. Gerontol. Ser. A Biol. Sci. Med. Sci.
          <year>2010</year>
<volume>65A</volume>
<fpage>1275</fpage>
<lpage>1284</lpage>
<pub-id pub-id-type="doi">10.1093/gerona/glq155</pub-id>
</element-citation>
</ref>
<ref id="B81-antioxidants-08-00111">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>A.-P.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C.-C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T.-C.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>T.-C.</given-names>
</name>
</person-group>
<article-title>Lifespan Extension and Sustained Expression of Stem Cell Phenotype of Human Breast Epithelial Stem Cells in a Medium with Antioxidants</article-title>
<source/>Stem Cells Int.
          <year>2016</year>
<volume>2016</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1155/2016/4591310</pub-id>
</element-citation>
</ref>
<ref id="B82-antioxidants-08-00111">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activated carbon N-acetylcysteine microcapsule protects against nonalcoholic fatty liver disease in young rats via activating telomerase and inhibiting apoptosis</article-title>
<source/>PLoS One
          <year>2018</year>
<volume>13</volume>
<elocation-id>e0189856</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0189856</pub-id>
<pub-id pub-id-type="pmid">29324774</pub-id>
</element-citation>
</ref>
<ref id="B83-antioxidants-08-00111">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Baltz</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Delay in oocyte aging in mice by the antioxidant N-acetyl-l-cysteine (NAC)</article-title>
<source/>Hum. Reprod.
          <year>2012</year>
<volume>27</volume>
<fpage>1411</fpage>
<lpage>1420</lpage>
<pub-id pub-id-type="doi">10.1093/humrep/des019</pub-id>
<pub-id pub-id-type="pmid">22357770</pub-id>
</element-citation>
</ref>
<ref id="B84-antioxidants-08-00111">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desjardins</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cacho-Valadez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Khaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Breton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hekimi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Antioxidants reveal an inverted U-shaped dose-response relationship between reactive oxygen species levels and the rate of aging in Caenorhabditis elegans</article-title>
<source/>Aging Cell
          <year>2017</year>
<volume>16</volume>
<fpage>104</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1111/acel.12528</pub-id>
<pub-id pub-id-type="pmid">27683245</pub-id>
</element-citation>
</ref>
<ref id="B85-antioxidants-08-00111">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhodes</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Braakhuis</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Performance and Side Effects of Supplementation with N-Acetylcysteine: A Systematic Review and Meta-Analysis</article-title>
<source/>Sport. Med.
          <year>2017</year>
<volume>47</volume>
<fpage>1619</fpage>
<lpage>1636</lpage>
<pub-id pub-id-type="doi">10.1007/s40279-017-0677-3</pub-id>
</element-citation>
</ref>
<ref id="B86-antioxidants-08-00111">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poljsak</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Milisav</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>The role of antioxidants in cancer, friends or foes?</article-title>
<source/>Curr. Pharm. Des.
          <year>2018</year>
<volume>24</volume>
<fpage>5234</fpage>
<lpage>5244</lpage>
<pub-id pub-id-type="doi">10.2174/1381612825666190123112647</pub-id>
<pub-id pub-id-type="pmid">30674247</pub-id>
</element-citation>
</ref>
<ref id="B87-antioxidants-08-00111">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poljsak</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Strategies for Reducing or Preventing the Generation of Oxidative Stress</article-title>
<source/>Oxid. Med. Cell. Longev.
          <year>2011</year>
<volume>2011</volume>
<fpage>1</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1155/2011/194586</pub-id>
</element-citation>
</ref>
<ref id="B88-antioxidants-08-00111">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Outschoorn</surname>
<given-names>U.E.</given-names>
</name>
<name>
<surname>Peiris-Pagés</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pestell</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Sotgia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lisanti</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Cancer metabolism: a therapeutic perspective</article-title>
<source/>Nat. Rev. Clin. Oncol.
          <year>2017</year>
<volume>14</volume>
<fpage>11</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1038/nrclinonc.2016.60</pub-id>
<pub-id pub-id-type="pmid">27141887</pub-id>
</element-citation>
</ref>
<ref id="B89-antioxidants-08-00111">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agarwal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muñoz-Nájar</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Klueh</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>S.-C.</given-names>
</name>
<name>
<surname>Claffey</surname>
<given-names>K.P.</given-names>
</name>
</person-group>
<article-title>N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer</article-title>
<source/>Am. J. Pathol.
          <year>2004</year>
<volume>164</volume>
<fpage>1683</fpage>
<lpage>1696</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)63727-3</pub-id>
<pub-id pub-id-type="pmid">15111315</pub-id>
</element-citation>
</ref>
<ref id="B90-antioxidants-08-00111">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elbini Dhouib</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Jallouli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Annabi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gharbi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Elfazaa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lasram</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>A minireview on N -acetylcysteine: An old drug with new approaches</article-title>
<source/>Life Sci.
          <year>2016</year>
<volume>151</volume>
<fpage>359</fpage>
<lpage>363</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2016.03.003</pub-id>
<pub-id pub-id-type="pmid">26946308</pub-id>
</element-citation>
</ref>
<ref id="B91-antioxidants-08-00111">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balansky</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Izzotti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Scatolini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>D’Agostini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>De Flora</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Induction by carcinogens and chemoprevention by N-acetylcysteine of adducts to mitochondrial DNA in rat organs</article-title>
<source/>Cancer Res.
          <year>1996</year>
<volume>56</volume>
<fpage>1642</fpage>
<lpage>1647</lpage>
<pub-id pub-id-type="pmid">8603414</pub-id>
</element-citation>
</ref>
<ref id="B92-antioxidants-08-00111">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Gal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>M.X.</given-names>
</name>
<name>
<surname>Wiel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sayin</surname>
<given-names>V.I.</given-names>
</name>
<name>
<surname>Akula</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Karlsson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dalin</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Akyürek</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Lindahl</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antioxidants can increase melanoma metastasis in mice</article-title>
<source/>Sci. Transl. Med.
          <year>2015</year>
<volume>7</volume>
<fpage>308re8</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aad3740</pub-id>
</element-citation>
</ref>
<ref id="B93-antioxidants-08-00111">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piskounova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Agathocleous</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huddlestun</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Leitch</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>DeBerardinis</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Oxidative stress inhibits distant metastasis by human melanoma cells</article-title>
<source/>Nature
          <year>2015</year>
<volume>527</volume>
<fpage>186</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1038/nature15726</pub-id>
<pub-id pub-id-type="pmid">26466563</pub-id>
</element-citation>
</ref>
<ref id="B94-antioxidants-08-00111">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Findley</surname>
<given-names>H.W.</given-names>
</name>
</person-group>
<article-title>Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: Interaction of IkBm and p53</article-title>
<source/>Oncogene
          <year>2003</year>
<volume>22</volume>
<fpage>8137</fpage>
<lpage>8144</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1206911</pub-id>
<pub-id pub-id-type="pmid">14603254</pub-id>
</element-citation>
</ref>
<ref id="B95-antioxidants-08-00111">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schafer</surname>
<given-names>Z.T.</given-names>
</name>
<name>
<surname>Grassian</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gerhart-Hines</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Irie</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Puigserver</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Brugge</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment</article-title>
<source/>Nature
          <year>2009</year>
<volume>461</volume>
<fpage>109</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1038/nature08268</pub-id>
<pub-id pub-id-type="pmid">19693011</pub-id>
</element-citation>
</ref>
<ref id="B96-antioxidants-08-00111">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watson</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Oxidants, antioxidants and the current incurability of metastatic cancers</article-title>
<source/>Open Biol.
          <year>2013</year>
<volume>3</volume>
<fpage>120144</fpage>
<pub-id pub-id-type="doi">10.1098/rsob.120144</pub-id>
<pub-id pub-id-type="pmid">23303309</pub-id>
</element-citation>
</ref>
<ref id="B97-antioxidants-08-00111">
<label>97.</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<collab>SBWIRE</collab>
</person-group>
<article-title>Global Acetylcysteine Market Size will Grow from US$ 490 Million to US$ 1650 Million by 2024</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.sbwire.com/press-releases/global-acetylcysteine-market-revenue-will-grow-at-223-cagr-to-2024-with-us-1650-million-market-size-1142001.htm">http://www.sbwire.com/press-releases/global-acetylcysteine-market-revenue-will-grow-at-223-cagr-to-2024-with-us-1650-million-market-size-1142001.htm</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-02-24">(accessed on 24 February 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B98-antioxidants-08-00111">
<label>98.</label>
<element-citation publication-type="web">
<article-title>Amazon.com, NAC powder</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.amazon.com/dp/B00F8HGA0E?aaxitk=XgCsjwjJY0uReP.ey4bLiQ&amp;pd_rd_i=B00F8HGA0E&amp;pf_rd_p=3fade48a-e699-4c96-bf08-bb772ac0e242&amp;hsa_cr_id=4339168660001&amp;sb-ci-n=productDescription&amp;sb-ci-v=BulkSupplements%2BNAC%2B(N-Acetyl%2BL-Cysteine)%2BPowder%2B(250%2Bgrams)&amp;th=1">https://www.amazon.com/dp/B00F8HGA0E?aaxitk=XgCsjwjJY0uReP.ey4bLiQ&amp;pd_rd_i=B00F8HGA0E&amp;pf_rd_p=3fade48a-e699-4c96-bf08-bb772ac0e242&amp;hsa_cr_id=4339168660001&amp;sb-ci-n=productDescription&amp;sb-ci-v=BulkSupplements%2BNAC%2B(N-Acetyl%2BL-Cysteine)%2BPowder%2B(250%2Bgrams)&amp;th=1</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-02-27">(accessed on 27 February 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B99-antioxidants-08-00111">
<label>99.</label>
<element-citation publication-type="web">
<article-title>WebMD</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.webmd.com/vitamins-supplements/ingredientreview-1018-N-ACETYL+CYSTEINE.aspx?drugid=1018&amp;drugname=N-ACETYL+CYSTEINE&amp;sortby=3">https://www.webmd.com/vitamins-supplements/ingredientreview-1018-N-ACETYL+CYSTEINE.aspx?drugid=1018&amp;drugname=N-ACETYL+CYSTEINE&amp;sortby=3</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-02-12">(accessed on 12 February 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B100-antioxidants-08-00111">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobley</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>McGlory</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Close</surname>
<given-names>G.L.</given-names>
</name>
</person-group>
<article-title>N-Acetylcysteine’s attenuation of fatigue after repeated bouts of intermittent exercise: Practical implications for tournament situations</article-title>
<source/>Int. J. Sport Nutr. Exerc. Metab.
          <year>2011</year>
<volume>21</volume>
<fpage>451</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="doi">10.1123/ijsnem.21.6.451</pub-id>
<pub-id pub-id-type="pmid">22089305</pub-id>
</element-citation>
</ref>
<ref id="B101-antioxidants-08-00111">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tardiolo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bramanti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mazzon</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases</article-title>
<source/>Molecules
          <year>2018</year>
<volume>23</volume>
<elocation-id>3305</elocation-id>
<pub-id pub-id-type="doi">10.3390/molecules23123305</pub-id>
</element-citation>
</ref>
<ref id="B102-antioxidants-08-00111">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garg</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Rizvi</surname>
<given-names>S.I.</given-names>
</name>
</person-group>
<article-title><italic>N</italic>-acetyl-L-cysteine attenuates oxidative damage and neurodegeneration in rat brain during aging</article-title>
<source/>Can. J. Physiol. Pharmacol.
          <year>2018</year>
<volume>96</volume>
<fpage>1189</fpage>
<lpage>1196</lpage>
<pub-id pub-id-type="doi">10.1139/cjpp-2018-0209</pub-id>
<pub-id pub-id-type="pmid">30107137</pub-id>
</element-citation>
</ref>
<ref id="B103-antioxidants-08-00111">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>N-acetyl-L-cysteine protects against cadmium-induced neuronal apoptosis by inhibiting ROS-dependent activation of Akt/mTOR pathway in mouse brain</article-title>
<source/>Neuropathol. Appl. Neurobiol.
          <year>2014</year>
<volume>40</volume>
<fpage>759</fpage>
<lpage>777</lpage>
<pub-id pub-id-type="doi">10.1111/nan.12103</pub-id>
<pub-id pub-id-type="pmid">24299490</pub-id>
</element-citation>
</ref>
<ref id="B104-antioxidants-08-00111">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreassen</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Dedeoglu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klivenyi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>A.I.</given-names>
</name>
</person-group>
<article-title>N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis</article-title>
<source/>Neuroreport
          <year>2000</year>
<volume>11</volume>
<fpage>2491</fpage>
<lpage>2493</lpage>
<pub-id pub-id-type="doi">10.1097/00001756-200008030-00029</pub-id>
<pub-id pub-id-type="pmid">10943709</pub-id>
</element-citation>
</ref>
<ref id="B105-antioxidants-08-00111">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pocernich</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Lange</surname>
<given-names>M.L.B.</given-names>
</name>
<name>
<surname>Sultana</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Nutritional approaches to modulate oxidative stress in Alzheimer’s disease</article-title>
<source/>Curr. Alzheimer Res.
          <year>2011</year>
<volume>8</volume>
<fpage>452</fpage>
<lpage>469</lpage>
<pub-id pub-id-type="doi">10.2174/156720511796391908</pub-id>
<pub-id pub-id-type="pmid">21605052</pub-id>
</element-citation>
</ref>
<ref id="B106-antioxidants-08-00111">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Aluise</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sultana</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>St. Clair</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Markesbery</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: Toward therapeutic modulation of mild cognitive impairment</article-title>
<source/>J. Neurosci. Res.
          <year>2010</year>
<volume>88</volume>
<fpage>2618</fpage>
<lpage>2629</lpage>
<pub-id pub-id-type="pmid">20648652</pub-id>
</element-citation>
</ref>
<ref id="B107-antioxidants-08-00111">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naik</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Tandan</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Dudhgaonkar</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Jadhav</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Kataria</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>V.R.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-L-cysteine in rats</article-title>
<source/>Eur. J. Pain
          <year>2006</year>
<volume>10</volume>
<fpage>573</fpage>
<pub-id pub-id-type="doi">10.1016/j.ejpain.2005.08.006</pub-id>
<pub-id pub-id-type="pmid">16214382</pub-id>
</element-citation>
</ref>
<ref id="B108-antioxidants-08-00111">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Spapen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Rogiers</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Effects of N-Acetyl-L-Cysteine on Regional Blood Flow during Endotoxic Shock</article-title>
<source/>Eur. Surg. Res.
          <year>1995</year>
<volume>27</volume>
<fpage>292</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1159/000129412</pub-id>
<pub-id pub-id-type="pmid">7589000</pub-id>
</element-citation>
</ref>
<ref id="B109-antioxidants-08-00111">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peake</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Leppard</surname>
<given-names>P.I.</given-names>
</name>
</person-group>
<article-title>N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock</article-title>
<source/>Crit. Care Med.
          <year>1996</year>
<volume>24</volume>
<fpage>1302</fpage>
<lpage>1310</lpage>
<pub-id pub-id-type="doi">10.1097/00003246-199608000-00006</pub-id>
<pub-id pub-id-type="pmid">8706483</pub-id>
</element-citation>
</ref>
<ref id="B110-antioxidants-08-00111">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arranz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fernández</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rodríguez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ribera</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>De la Fuente</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The glutathione precursor N-acetylcysteine improves immune function in postmenopausal women</article-title>
<source/>Free Radic. Biol. Med.
          <year>2008</year>
<volume>45</volume>
<fpage>1252</fpage>
<lpage>1262</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2008.07.014</pub-id>
<pub-id pub-id-type="pmid">18694818</pub-id>
</element-citation>
</ref>
<ref id="B111-antioxidants-08-00111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skvarc</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>O.M.</given-names>
</name>
<name>
<surname>Byrne</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marriott</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The effect of N-acetylcysteine (NAC) on human cognition – A systematic review</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2017</year>
<volume>78</volume>
<fpage>44</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.04.013</pub-id>
<pub-id pub-id-type="pmid">28438466</pub-id>
</element-citation>
</ref>
<ref id="B112-antioxidants-08-00111">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logan</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Chronic fatigue syndrome: Oxidative stress and dietary modifications</article-title>
<source/>Altern. Med. Rev.
          <year>2001</year>
<volume>6</volume>
<fpage>450</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="pmid">11703165</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="antioxidants-08-00111-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">antioxidants-08-00111-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Overview of Food and Drug Administration FDA-approved N-acetyl-cysteine (NAC) drugs and their indications.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Route</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Administration</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Strength</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">No.*</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Medical Condition/<break></break>Therapy Type</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Injectable</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Intravenous</td>
<td align="center" colspan="1" rowspan="1" valign="middle">200 mg/mL<break></break>(6 g/30 mL)</td>
<td align="center" colspan="1" rowspan="1" valign="middle">7</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Poisoning/<break></break>antidote</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Acetaminophen overdose reduction;<break></break>Prevention of acute hepatic injury;<break></break>Hepatic injury from repeated supratherapeutic ingestion.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Effervescent tablet</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Oral</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">500 mg<break></break>2.5 g</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Solution</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Oral</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10%<break></break>20%</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Bronchopulmonary disorders/<break></break>Adjuvant therapy</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Abnormal, viscid, inspissated mucous secretions in chronic** and acute*** bronchopulmonary disease;<break></break>Pulmonary complications of cystic fibrosis;<break></break>Tracheostomy care;<break></break>Pulmonary complications associated with surgery;<break></break>Use during anesthesia;<break></break>Post-traumatic chest conditions;<break></break>Atelectasis due to mucous obstruction and diagnostic bronchial studies****.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Solution</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inhalation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">10%<break></break>20%</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>*: Number of drugs, currently on the market. **: Chronic bronchopulmonary disease: chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis, and primary amyloidosis of the lung. ***: Acute bronchopulmonary disease: pneumonia, bronchitis, and tracheobronchitis. ****: Diagnostic bronchial studies: bronchograms, bronchospirometry, and bronchial wedge catheterization.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="antioxidants-08-00111-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">antioxidants-08-00111-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>NAC clinical trials registered at ClinicalTrials.gov [<xref ref-type="bibr" rid="B48-antioxidants-08-00111">48</xref>]. The number of studies is displayed according to the study status, tested medical conditions of currently active studies, tested medical conditions in completed studies, study phase and tested medical conditions of currently active studies, study phase, and tested medical conditions of completed studies.</p>
</caption>
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
<bold>Status</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
<bold>Count</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Completed</td>
<td align="center" colspan="1" rowspan="1" valign="middle">159</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Not yet recruiting</td>
<td align="center" colspan="1" rowspan="1" valign="middle">14</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Active</td>
<td align="center" colspan="1" rowspan="1" valign="middle">54</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Withdrawn/terminated/suspended</td>
<td align="center" colspan="1" rowspan="1" valign="middle">24</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Unknown status</td>
<td align="center" colspan="1" rowspan="1" valign="middle">40</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Grand Total</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>291</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Medical Conditions (Active Studies)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Count</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cancer/chemotherapy side effects</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cardiovascular diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Genetic disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Graft/stem cell complications/trauma</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Infectious diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Metabolic diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Poisoning antidote</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Pulmonary diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Surgery complications/trauma</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Grand Total</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>54</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Medical Conditions (Completed Studies)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Count</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">17</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Blood disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cancer/chemotherapy side effects</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cardiovascular diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Dermatologic disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">15</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Genetic disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Infectious diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Metabolic diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Muscle disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">24</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Ophthalmological diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ORL</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Other</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Poisoning antidote</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Pulmonary diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">13</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Renal disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">31</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Surgery complications/trauma</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Grand Total</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>159</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Phase/Medical Conditions (Active Studies)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Count</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Early Phase 1</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>5</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Metabolic diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pulmonary diseases</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Not Applicable</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>10</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cardiovascular diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Graft/stem cell complications/trauma</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Surgery complications/trauma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 1</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>4</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cancer/chemotherapy side effects</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Poisoning antidote</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 1|Phase 2</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>3</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cancer/chemotherapy side effects</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 2</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>13</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cancer/chemotherapy side effects</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Genetic disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Graft/stem cell complications/trauma</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Infectious diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 2|Phase 3</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>3</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Graft/stem cell complications/trauma</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 3</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>8</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cancer/chemotherapy side effects</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cardiovascular diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Surgery complications/trauma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 4</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>8</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Graft/stem cell complications/trauma</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Surgery complications/trauma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Grand Total</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>54</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Phase/Medical Conditions (Completed Studies)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Count</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Early Phase 1</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>3</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Blood disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ORL</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Not Applicable</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>18</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cardiovascular diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Metabolic diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Pulmonary diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Renal disorders</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 1</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>22</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cancer/chemotherapy side effects</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cardiovascular diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Ophthalmological diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ORL</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Other</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Pulmonary diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Renal disorders</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 1|Phase 2</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>12</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Blood disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Infectious diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Metabolic diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Renal disorders</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 2</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>47</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Blood disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cancer/chemotherapy side effects</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cardiovascular diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Dermatologic disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Genetic disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Infectious diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Metabolic diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Muscle disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">14</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Ophthalmological diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ORL</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Pulmonary diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Renal disorders</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 2|Phase 3</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>8</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ORL</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Renal disorders</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 3</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>20</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Blood disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cardiovascular diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Dermatologic disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Infectious diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Pulmonary diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Renal disorders</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Phase 4</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>29</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Addiction</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Cardiovascular diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gastrointestinal diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Metabolic diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Neuro/psychiatric disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Obstetrics</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">ORL</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Poisoning antidote</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Pulmonary diseases</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Renal disorders</td>
<td align="center" colspan="1" rowspan="1" valign="middle">7</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Surgery complications/trauma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Grand Total</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>159</bold>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>ORL: Otorhinolaryngology.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="antioxidants-08-00111-t003" orientation="portrait" position="float">
<object-id pub-id-type="pii">antioxidants-08-00111-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>Medical conditions investigated by withdrawn, terminated, and suspended studies listed by ClinicalTrials.gov [<xref ref-type="bibr" rid="B48-antioxidants-08-00111">48</xref>]. Listed: number of trials listed at ClinicalTrials.gov [<xref ref-type="bibr" rid="B48-antioxidants-08-00111">48</xref>]; Phase: study phase; N/A: not applicable.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Status/Medical Condition</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Listed</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Phase</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Termination Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>SUSPENDED</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Autoimmune Disorders</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Systemic Lupus Erythematosus</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1|2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Short of funds</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Cardiovascular Diseases</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cardiovascular Disease|Renal Insufficiency, Acute|Cardiopulmonary Bypass</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Opposite result</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Infectious Diseases</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hepatitis C</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Short of funds</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Metabolic diseases</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Insulin Resistance|Metabolic Syndrome</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>TERMINATED/</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">15</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Addiction</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Acetaminophen Overdose</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Insufficient enrollment</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Prevention of Hangover Using NAC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Insufficient enrollment</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Cancer/Chemotherapy Side Effects</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Bone Marrow Suppression|Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Long-term Effects Secondary to Cancer Therapy in Children</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">N/A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Malignant Ovarian Endometrioid Tumor|Malignant Ovarian Serous Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Slow accrual</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Gastrointestinal Diseases</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Acute Liver Failure|Fulminant Hepatic Failure</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Insufficient enrollment</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Drug Induced Liver Injury</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2 sepsis cases after steroid admin.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Genetic disorders</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cystic Fibrosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Insufficient enrollment</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Infectious Diseases</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>Helicobacter pylori</italic> Infection</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1|2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Efficacy of eradication: 2 out of 31</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Metabolic diseases</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Type 2 Diabetes Mellitus|Hypertension</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Neuro/Psychiatric Disorders</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Borderline Personality Disorder|Self-Injurious Behavior</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Poor subject compliance</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Bulimia Nervosa</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2|3; 3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">No meaningful improvements</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Obsessive-Compulsive Disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Insufficient enrollment</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Pulmonary Diseases</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">COPD|Chronic Bronchitis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PI’s discretion</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Renal Disorders</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Chronic Kidney Failure</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Surgery Complications/Trauma</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ischemic Reperfusion Injury|Insufficiency; Hepatic, Postoperative|Liver Tumour</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>WITHDRAWN/</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Cancer/Chemotherapy Side Effects</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ovarian Carcinoma, Stage 3 or 4|Epithelial Ovarian Carcinoma|Primary Peritoneal Carcinoma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">No funding for the cost of NAC</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Gastrointestinal Diseases</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Liver Failure|Liver Failure, Acute|Drug Induced Liver Injury|Prevention and Control|Fever</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Short of funds</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Neuro/Psychiatric Disorders</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Autistic Disorder|Seizures|Irritability</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">N/A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">No eligible subjects located</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Posttraumatic Stress Disorder</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cancelled research project</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Grand Total</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>23</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>